Other
Payments for Repurchase of Common Stock
West Pharmaceutical Services Payments for Repurchase of Common Stock increased by 59420.0% to $297.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 122.9%, from $133.50M to $297.60M. Over 2 years (FY 2022 to FY 2024), Payments for Repurchase of Common Stock shows an upward trend with a 66.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalLower is better
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026Apr 23, 2026
How to read this metric
Higher spending indicates a commitment to returning capital to shareholders or offsetting dilution from stock-based compensation.
Detailed definition
The cash outflow associated with the company's repurchase of its own common shares from the open market. This is a prima...
Peer comparison
Standard capital return metric for mature public companies.
Metric ID:
other_payments_for_repurchase_of_common_stockHistorical Data
15 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $147.10M | $28.60M | $27.20M | $0.00 | $60.10M | $173.40M | $27.80M | $177.00M | $267.00M | $187.10M | $52.40M | $54.40M | $133.50M | $500.00K | $297.60M |
| QoQ Change | — | -80.6% | -4.9% | -100.0% | — | +188.5% | -84.0% | +536.7% | +50.8% | -29.9% | -72.0% | +3.8% | +145.4% | -99.6% | >999% |
| YoY Change | — | — | — | — | -59.1% | +506.3% | +2.2% | — | +344.3% | +7.9% | +88.5% | -69.3% | -50.0% | -99.7% | +122.9% |
Range$0.00 – $297.60M
CAGR+22.3%
Avg YoY Growth+79.4%
Median YoY Growth+5.1%
Payments for Repurchase of Common Stock at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's payments for repurchase of common stock?
- West Pharmaceutical Services (WST) reported payments for repurchase of common stock of $297.60M in Q1 2026.
- How has West Pharmaceutical Services's payments for repurchase of common stock changed year-over-year?
- West Pharmaceutical Services's payments for repurchase of common stock increased by 122.9% year-over-year, from $133.50M to $297.60M.
- What is the long-term trend for West Pharmaceutical Services's payments for repurchase of common stock?
- Over 2 years (2022 to 2024), West Pharmaceutical Services's payments for repurchase of common stock has grown at a 66.3% compound annual growth rate (CAGR), from $202.90M to $560.90M.
- What does payments for repurchase of common stock mean?
- Cash spent by the company to buy back its own common stock.